Cargando…
Prospective assessment using (18)F-FDG PET/CT as a novel predictor for early response to PD-1 blockade in non-small-cell lung cancer
Anti-programmed death-1 (PD-1) blockade is a standard treatment for advanced non-small-cell lung cancer (NSCLC). However, no appropriate modality exists for monitoring its therapeutic response immediately after initiation. Therefore, we aimed to elucidate the clinical relevance of (18)F-FDG PET/CT v...
Autores principales: | Yamaguchi, Ou, Kaira, Kyoichi, Naruse, Ichiro, Umeda, Yukihiro, Honda, Takeshi, Watanabe, Satoshi, Ichikawa, Kosuke, Tateishi, Kazunari, Kasahara, Norimitsu, Higuchi, Tetsuya, Hashimoto, Kosuke, Shinomiya, Shun, Miura, Yu, Shiono, Ayako, Mouri, Atsuto, Imai, Hisao, Iizuka, Kunihiko, Ishizuka, Tamotsu, Minato, Koichi, Suda, Satoshi, Kagamu, Hiroshi, Mori, Keita, Kuji, Ichiei, Seki, Nobuhiko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9276827/ https://www.ncbi.nlm.nih.gov/pubmed/35821395 http://dx.doi.org/10.1038/s41598-022-15964-3 |
Ejemplares similares
-
Comparative analysis of different response criteria at early phase after PD-1 blockade in non-small lung cancer
por: Kaira, Kyoichi, et al.
Publicado: (2023) -
Tumor metabolic volume by (18)F-FDG-PET as a prognostic predictor of first-line pembrolizumab for NSCLC patients with PD-L1 ≥ 50%
por: Yamaguchi, Ou, et al.
Publicado: (2020) -
Potential of FDG-PET as Prognostic Significance after anti-PD-1 Antibody against Patients with Previously Treated Non-Small Cell Lung Cancer
por: Hashimoto, Kosuke, et al.
Publicado: (2020) -
Effectiveness of EGFR‐TKI rechallenge immediately after PD‐1 blockade failure
por: Kaira, Kyoichi, et al.
Publicado: (2021) -
Pre‐existing interstitial lung disease does not affect prognosis in non‐small cell lung cancer patients with PD‐L1 expression ≥50% on first‐line pembrolizumab
por: Yamaguchi, Ou, et al.
Publicado: (2020)